Ketorolac tromethamine doesn't reduce risk of severe ROP development

Article

Administering ketorolac tromethamine ophthalmic solution to preterm infants does not reduce the risk of developing severe retinopathy of prematurity (ROP).

Administering ketorolac tromethamine ophthalmic solution to preterm infants does not reduce the risk of developing severe retinopathy of prematurity (ROP), claims a study in the Journal of Pediatric Ophthalmology and Strabismus.

Dr Carmen Giannantonio et al., Division of Neonatology, Department of Pediatrics, Catholic University Sacred Heart, Rome, Italy, included 47 premature newborn infants who weighed 1000 g or less at a gestational age (GA) of 29 weeks.

Each infant was administered ketorolac tromethamine ophthalmic solution in one eye and a placebo solution in the other eye.

Out of the patients assessed, 45 infants developed ROP. Of the patients with ROP, six presented with various stages of ROP between the two eyes- four experienced a better outcome in the eye that received ketorolac tromethamine.

When evaluated according to GA the differences between ROP staging were not significant and no significant side effects were reported.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
© 2025 MJH Life Sciences

All rights reserved.